What is Lifesci Capital's Forecast for RCKT Q2 Earnings?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Equities research analysts at Lifesci Capital issued their Q2 2025 earnings per share (EPS) estimates for shares of Rocket Pharmaceuticals in a research note issued to investors on Tuesday, May 27th. Lifesci Capital analyst C. Jubinville expects that the biotechnology company will earn ($0.56) per share for the quarter. The consensus estimate for Rocket Pharmaceuticals' current full-year earnings is ($2.83) per share. Lifesci Capital also issued estimates for Rocket Pharmaceuticals' Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.56) EPS and FY2025 earnings at ($2.24) EPS.

Several other analysts have also recently issued reports on the company. Wedbush reaffirmed an "outperform" rating and set a $32.00 price objective on shares of Rocket Pharmaceuticals in a report on Friday, May 16th. JPMorgan Chase & Co. restated a "neutral" rating on shares of Rocket Pharmaceuticals in a report on Wednesday. Bank of America decreased their price target on Rocket Pharmaceuticals from $32.00 to $9.00 and set a "buy" rating on the stock in a report on Wednesday. Chardan Capital decreased their price target on Rocket Pharmaceuticals from $46.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday. Finally, Jefferies Financial Group restated a "hold" rating on shares of Rocket Pharmaceuticals in a report on Wednesday. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $21.21.

Rocket Pharmaceuticals Price Performance

Shares of RCKT traded down $0.14 during mid-day trading on Thursday, hitting $2.48. 7,402,317 shares of the stock were exchanged, compared to its average volume of 1,873,470. The company has a market cap of $264.83 million, a PE ratio of -0.90 and a beta of 1.02. Rocket Pharmaceuticals has a 52-week low of $2.19 and a 52-week high of $26.98. The firm has a 50-day moving average of $6.20 and a two-hundred day moving average of $9.49. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.02. During the same period in the previous year, the firm earned ($0.66) EPS.

Insider Transactions at Rocket Pharmaceuticals

In other news, CEO Gaurav Shah purchased 20,000 shares of the company's stock in a transaction dated Thursday, April 10th. The shares were acquired at an average price of $5.08 per share, with a total value of $101,600.00. Following the transaction, the chief executive officer now owns 792,680 shares of the company's stock, valued at $4,026,814.40. This represents a 2.59% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kinnari Patel purchased 21,099 shares of the company's stock in a transaction dated Wednesday, April 9th. The shares were purchased at an average cost of $4.70 per share, for a total transaction of $99,165.30. Following the transaction, the insider now directly owns 26,774 shares in the company, valued at approximately $125,837.80. This represents a 371.79% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 24.76% of the company's stock.

Hedge Funds Weigh In On Rocket Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Covestor Ltd grew its stake in Rocket Pharmaceuticals by 33,166.7% in the fourth quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 1,990 shares during the last quarter. Signaturefd LLC grew its stake in Rocket Pharmaceuticals by 83.6% in the first quarter. Signaturefd LLC now owns 9,024 shares of the biotechnology company's stock valued at $60,000 after purchasing an additional 4,108 shares during the last quarter. Harbour Investments Inc. grew its stake in Rocket Pharmaceuticals by 51.9% in the fourth quarter. Harbour Investments Inc. now owns 5,385 shares of the biotechnology company's stock valued at $68,000 after purchasing an additional 1,840 shares during the last quarter. KBC Group NV grew its stake in Rocket Pharmaceuticals by 159.6% in the fourth quarter. KBC Group NV now owns 5,475 shares of the biotechnology company's stock valued at $69,000 after purchasing an additional 3,366 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new position in Rocket Pharmaceuticals in the first quarter valued at about $69,000. Institutional investors own 98.39% of the company's stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.